Paulina Horvei

Paulina Horvei

Auto-generated profile, based on publicly available information

Paulina Horvei

T Cell Engineering, Mayo Clinic, Rochester, MN

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2024 in Blood
Verified
Journal Article
Open access
PDF file
RSR. Leo Sakemura
R. Leo Sakemura
CRClaudia Manriquez Roman
Claudia Manriquez Roman
PHPaulina Horvei
Paulina Horvei
ESElizabeth L. Siegler
Elizabeth L. Siegler
JGJames H. Girsch
James H. Girsch
SKSaad S. Kenderian
Saad S. Kenderian
In the development of various strategies of anti-CD19 immunotherapy for the treatment of B-cell malignancies, it remains unclear whether CD19 monoclonal antibody therapy impairs subsequent CD19-targeted chimeric antigen receptor T-cell (CART19) therapy. We evaluated the potential interference between the CD19-targeting monoclonal antibody tafasitamab and CART19 treatment in preclinical models. Concomitant treatment with tafasitamab and CART19 showed major CD19 binding competition, which led to CART19 functional impairment. However, when CD19+ cell lines were pretreated with tafasitamab overnight and the unbound antibody was subsequently removed from the culture, CART19 function was not affected. In preclinical in vivo models, tafasitamab pretreatment demonstrated reduced incidence and severity of cytokine release syndrome and exhibited superior antitumor effects and overall survival compared with CART19 alone. This was associated with transient CD19 occupancy with tafasitamab, which in turn resulted in the inhibition of CART19 overactivation, leading to diminished CAR T apoptosis and pyroptosis of tumor cells.

28 June 2023 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
RSR. Leo Sakemura
R. Leo Sakemura
MHMehrdad Hefazi
Mehrdad Hefazi
MCMichelle J. Cox
Michelle J. Cox
ESElizabeth L. Siegler
Elizabeth L. Siegler
SSSutapa Sinha
Sutapa Sinha
SKSaad S. Kenderian
Saad S. Kenderian
The receptor tyrosine kinase AXL is a member of the TYRO3, AXL, and proto-oncogene tyrosine-protein kinase MER family and plays pleiotropic roles in cancer progression. AXL is expressed in immunosuppressive cells, which contributes to decreased efficacy of immunotherapy. Therefore, we hypothesized that AXL inhibition could serve as a strategy to overcome resistance to chimeric antigen receptor T (CAR T)–cell therapy. To test this, we determined the impact of AXL inhibition on CD19-targeted CAR T (CART19)–cell functions. Our results demonstrate that T cells and CAR T cells express high levels of AXL. Specifically, higher levels of AXL on activated Th2 CAR T cells and M2-polarized macrophages were observed. AXL inhibition with small molecules or via genetic disruption in T cells demonstrated selective inhibition of Th2 CAR T cells, reduction of Th2 cytokines, reversal of CAR T-cell inhibition, and promotion of CAR T-cell effector functions. AXL inhibition is a novel strategy to enhance CAR T-cell functions through two independent, but complementary, mechanisms: targeting Th2 cells and reversing myeloid-induced CAR T-cell inhibition through selective targeting of M2-polarized macrophages.



28 July 2023
Verified
Other
Open access
RSR. Leo Sakemura
R. Leo Sakemura
MHMehrdad Hefazi
Mehrdad Hefazi
MCMichelle J. Cox
Michelle J. Cox
ESElizabeth L. Siegler
Elizabeth L. Siegler
SSSutapa Sinha
Sutapa Sinha
SKSaad S. Kenderian
Saad S. Kenderian
Supplementary Table S2 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells

26 November 2025
Verified
Other
Open access
RSR. Leo Sakemura
R. Leo Sakemura
MHMehrdad Hefazi
Mehrdad Hefazi
MCMichelle J. Cox
Michelle J. Cox
ESElizabeth L. Siegler
Elizabeth L. Siegler
SSSutapa Sinha
Sutapa Sinha
SKSaad S. Kenderian
Saad S. Kenderian
Supplementary Table S2 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells